Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | SI | P14410 | 1/20 | 0.55 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.55 |
| ▸ | IGF1R | P08069 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 7/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 2/20 | 0.41 |
| ▸ | GLS2 | Q9UI32 | 2/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | INSR | P06213 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7556213 | 1.00 | MGAM (0.55) | MGAMGAASIMGAM2IGF1R | |
| SCHEMBL7519438 | 0.87 | MGAM (0.55) | MGAMGAASIMGAM2IGF1R | |
| SCHEMBL7519434 | 0.87 | MGAM (0.55) | MGAMGAASIMGAM2IGF1R | |
| SCHEMBL7520980 | 0.85 | MGAM (0.53) | MGAMGAASIMGAM2IGF1R | |
| SCHEMBL7520977 | 0.85 | MGAM (0.53) | MGAMGAASIMGAM2IGF1R | |
| SCHEMBL7509197 | 0.83 | MGAM (0.60) | MGAMGAASIMGAM2IGF1R | |
| SCHEMBL7509203 | 0.83 | MGAM (0.60) | MGAMGAASIMGAM2IGF1R | |
| SCHEMBL7513237 | 0.82 | BRD4 (0.43) | HTTHPGDBRD4 | |
| SCHEMBL7515553 | 0.82 | MGAM (0.56) | MGAMGAASIMGAM2IGF1R | |
| SCHEMBL7515220 | 0.82 | MGAM (0.72) | MGAMGAASIMGAM2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6452014-B1 | THIAZOLIDINEDIONE COMPOUNDS | GERON CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| WO-2002051409-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | TERT, TERF2, POT1 | MGAM 3441/4885GAA 625/4885SI 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.